Health Care
More on Health Care
Washington, D.C. (July 11, 2019)—Rep. Elijah E. Cummings, the Chairman of the Committee on Oversight and Reform, convened a hearing entitled "The Trump Administration's Attack on the ACA: Reversal in Court Case Threatens Health Care for Millions of Americans" to examine the implications of the Trump Administration's sudden decision to reverse its own previous legal position in Texas v.
Washington, D.C. (July 8, 2019)—On Thursday, July 11, 2019, at 10:00 a.m., the Committee on Oversight and Reform will hold a hearing with trauma survivors, public health experts, and government officials to examine childhood trauma in the United States.
WHERE: 2154 Rayburn House Office Building
WHEN: Thursday, July 11, 2019
TIME: 10:00 a.m.
| Washington, D.C. (June 27, 2019)— Rep. Elijah E. Cummings, the Chairman of the Committee on Oversight and Reform, Rep. Ro Khanna, Rep. Alexandria Ocasio-Cortez, and Rep. Ayanna Pressley sent a letter to Gilead Sciences seeking information about patents held by the federal government for the HIV prevention therapy known as Truvada for pre-exposure prophylaxis (PrEP). |
Washington, D.C. (June 26, 2019)—Today, Rep. Elijah E. Cummings, the Chairman of the Committee on Oversight and Reform, sent a letter to the Acting Director of the Office of Management and Budget (OMB), Russell Vought, requesting his testimony on the decision by the Trump Administration to reverse its own legal position in Texas v.
Washington, D.C. (June 18, 2019)—On Wednesday, June 19, 2019, Rep. Elijah E. Cummings, the Chairman of the Committee on Oversight and Reform, will convene a third hearing on the opioid epidemic, entitled "Medical Experts: Inadequate Federal Approach to Opioid Treatment and the Need to Expand Care."
WASHINGTON, D.C. (June 18, 2019) – U.S. Senator Debbie Stabenow (D-MI), Ranking Member of the Health Subcommittee of the Senate Finance Committee, and U.S. Congressman Elijah Cummings (D-MD), Chairman of the House Oversight and Reform Committee, today called for a Government Accountability Office review of how the Department of Health and Human Services (HHS) prevents pharmaceutical companies from infringing on government-owned patents.